Twice-Daily Triple Nucleoside Intensification Treatment with Lamivudine-Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET Study

This open-label, multicenter, single-arm clinical trial assessed the 48-week efficacy of a twice-daily triple nucleoside reverse-transcriptase inhibitor regimen containing a lamivudine (150 mg)—zidovudine (300 mg) combination tablet (COM) and abacavir (ABC; 300 mg) in 87 antiretroviral therapy-experienced, protease inhibitor—naive patients infected with human immunodeficiency virus type 1 (HIV-1). At baseline, the median plasma HIV-1 RNA level was 3.10 log10 copies/mL, and the median CD4 cell count was 506 cells/mm3. An intent-to-treat: observed analysis showed that, at weeks 24 and 48 of treatment, HIV-1 RNA level was